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does not differ in terms of average inhibition of platelet aggrega-
tion than clopidogrel. This again emphasizes that individual drug
response more than average potency of the 2 tested drugs explain
our findings. In keeping with our findings, only a minority (15%)
of poor responders to clopidogrel displayed a normal response to the
same drug after doubling the dose in a recent phase II study ( 2).
We strongly disagree that “The major take-home message
conveyed to the readership is that clopidogrel-treated patients may
be switched to ticlopidine if ‘resistance’ is determined by the
platelet tests.” Indeed, in keeping with the conclusion statement of
our recent paper, our findings, especially in the current pre-
prasugrel era, should affect the design of future trials rather than
clinical practice. The observation that ticlopidine, at the currently
recommended dosage, unlike clopidogrel at double regimen, over-
comes resistance to clopidogrel in the great majority of cases may
prompt randomized controlled studies where standard care after
stenting (i.e., clopidogrel 75 mg/day) is compared with tailored
antiplatelet treatment (clopidogrel 150 mg/day in nonresponders
to clopidogrel standard regimen or ticlopidine in nonresponders to
clopidogrel double dose). Until such a study becomes available,
both the risks and benefits of tailoring treatment based on target
platelet inhibition will remain hypothetical.
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Relationship Between Atrial
Fibrillation and Left Atrial Size
The paper by Bangalore et al. (1) in a recent issue of the Journal
evaluated the role of diastolic dysfunction as measured by left atrial
(LA) size and the associated risk for adverse cardiovascular events
in patients undergoing stress echocardiography. The authors report
indexed LA size as a predictor of cardiac events independent of
traditional clinical risk factors. Patients with significant mitral
valve disease and with significant left ventricular systolic dysfunc-
tion were appropriately excluded from this study. However, atrial
fibrillation (AF) is another important potential confounder, be-
cause is it known to affect LA remodeling and geometry (2) and is
a known risk factor for cardiovascular events, particularly stroke.
This remodeling effect is independent of loading conditions within
the LA and can occur in both chronic and paroxysmal AF (3). It
would be important to know whether AF was included in the
multivariate analysis as well as the percent of patients who carried
the diagnosis of AF. Furthermore, if LA size could predict
prognosis in the subgroup of patients without AF to a similar
extent as that reported in this study, this would lend further
validity to the authors’ argument to incorporate LA size into the
prognostic interpretation of stress testing.
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Reply
We agree with the comment of Dr. Goldberg about the relation-
ships between atrial fibrillation (AF) and left atrial (LA) size. In
the AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) study of 4,060 patients with AF only 33%
of patients had a normal LA size (1). Patients with dilated left
atrium are more prone to AF, and patients with AF and a dilated
left atrium are more likely to remain in AF than those with normal
LA dimensions. Atrial fibrillation is also known to affect LA
remodeling and geometry. In a prospective echocardiographic
follow-up of patients with AF, atrial enlargement was shown to
occur as a consequence of AF (2). Regardless of whether LA
enlargement is a cause for or a consequence of AF, the prognosis
is worse compared with patients with a normal LA size.
In our study cohort of 2,705 patients undergoing stress
echocardiography (3), only 63 (2.3%) patients had either AF or
atrial flutter. Analysis performed after excluding this cohort
showed that LA size was able to further risk stratify patients
undergoing stress echocardiography (Fig. 1). The results were
similar for the multivariable analysis and incremental prognostic
value analysis. Thus even after excluding patients with AF/atrial
flutter, LA size provided independent and incremental value
over standard risk factors, including left ventricular systolic
dysfunction and ischemia, and was a powerful prognosticator.
Therefore, it should be routinely used in the prognostic inter-
pretation of stress echocardiography.
776 Correspondence JACC Vol. 51, No. 7, 2008
February 19, 2008:773–7
